ClinicalTrials.gg
RecruitingNCT06412497Updated Jun 3, 2026

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

A Phase 2 interventional study of Rituximab and Rabbit ATG in Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia and Acquired Pure Red Cell Aplasia, sponsored by Masonic Cancer Center, University of Minnesota. Recruiting at 1 site in United States. Open to participants aged 0 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
0 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies testing cyclophosphamide in Anemia, Aplastic — 6 open to participants now, 8 under way, none of them phase 3. Cyclophosphamide · Anemia, Aplastic.

Planned enrollment
8th of 42
60 · median 31
Started
2024
with 1 other
Phase 2
26 of 44
5 open now
Registered
44th of 44
by date
Lead sponsor
2 of 44
Masonic Cancer Center, University of Minnesota

Among the 44 studies testing cyclophosphamide in Anemia, Aplastic, this one is the 8th largest by planned enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 in phase 2, and was the 44th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

6 of the 44 studies testing cyclophosphamide in Anemia, Aplastic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: 0 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing cyclophosphamide in Anemia, Aplastic, or all of them as a file.
02

Study summary

A phase II trial of a reduced intensity conditioned (RIC) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for idiopathic severe aplastic anemia (SAA), paroxysmal nocturnal hemoglobinuria (PNH), acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT) utilizing population pharmacokinetic (popPK)-guided individual dosing of pre-transplant conditioning and differential dosing of low dose total body irradiation based on age, presence of myelodysplasia and/or clonal hematopoiesis.

03

Conditions studied

  • Severe Aplastic Anemia
  • Acquired Amegakaryocytic Thrombocytopenia
  • Acquired Pure Red Cell Aplasia
  • Paroxysmal Nocturnal Hemoglobinuria

Keywords

  • HCT
  • RIC
  • SAA
  • PTCy
  • aAT
  • aPRCA
04

Who can participate

Ages eligible
0 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Idiopathic Severe Aplastic Anemia (SAA), characterized by one of the following:

    1. cytopenia(s), with 1+ of the following:

      1. \<20,000/uL or transfusion dependent
      2. \<500/uL without hematopoietic growth factor support
      3. Absolute reticulocyte count \<60,000/uL AND bone marrow cellularity \<50% (with \< 30% residual hematopoietic cells)
    2. Early myelodysplastic features (bone marrow (BM) blasts \<5%), without history of MDS/AML pre-treatment.
    3. Idiopathic SAA with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd HCT
  • Paroxysmal Nocturnal Hemoglobinuria (PNH), including AA-PNH overlap syndrome, acquired pure red cell aplasia (aPRCA), or acquired amegakaryocytic thrombocytopenia (aAT), characterized by one of the following:

    1. Refractory cytopenia(s), with 1+ of the following:

      1. Platelets \<20,000/uL or transfusion dependent
      2. Absolute neutrophil count \<500/uL without hematopoietic growth factor support
      3. Absolute reticulocyte count \<60,000/uL or red cell transfusion dependent AND Bone marrow evidence of 1 to 3-lineage aplasia OR peripheral blood PNH clone >/= 10%
    2. Early myelodysplastic features (bone marrow (BM) blasts \<5%) without history of MDS/AML pre-treatment.
    3. Idiopathic PNH, aPRCA, or aAT with post-HCT graft failure (blood/marrow donor chimerism \<5%) requiring a 2nd allogeneic HCT
  • Adequate organ function within 30 days of conditioning regimen

Exclusion criteria

Exclusion Criteria:

  • Pregnant, breastfeeding or intending to become pregnant during the study. Persons of must have a negative pregnancy test (serum or urine) within 7 days of the start of treatment
  • Uncontrolled infection
  • Evidence of moderate or severe portal fibrosis or cirrhosis on
  • Known allergy to any of the study components
  • Prior radiation therapy deemed excessive by radiation therapist for proposed low dose TBI exposure on this protocol
  • Diagnosis of an inherited bone marrow failure disorder such as Fanconi anemia, Telomere biology disorder, or Schwachman-Diamond syndrome, unless reviewed by the principal investigator and deemed appropriate for this approach (e.g. GATA2 deficiency)
  • Advanced myelodysplastic syndrome (MDS; BM blasts >5%) or acute myeloid leukemia
  • Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
  • Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Arm A: No clonal hematopoiesis

    Participants 25 years of age and younger with no clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.

    Drug: Rituximab · Drug: Rabbit ATG · Drug: Cyclophosphamide · Drug: Fludarabine · Radiation: Total Body Irradiation · Biological: Cell Infusion · Drug: Post-Transplant G-CSF · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

  • Experimental
    Arm B: Clonal hematopoiesis

    Participants 25-75 years old and/or with clonal hematopoiesis. Active study treatment includes the conditioning regimen followed by the stem cell infusion and GvHD prophylaxis through day +180. Supportive care and follow up activities continue through two years post HCT.

    Drug: Rituximab · Drug: Rabbit ATG · Drug: Cyclophosphamide · Drug: Fludarabine · Radiation: Total Body Irradiation · Biological: Cell Infusion · Drug: Post-Transplant G-CSF · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

Interventions

  • For patients with EBV IgG seropositivity or EBV PCR positivity on pre-transplant evaluations, Rituximab 375 mg/m2 is given IV once on day -14 (+/-2 day) in the outpatient setting. Pre-medicate 30 minutes prior to rituximab with methylprednisolone (1 mg/kg) IV, acetaminophen 15 mg/kg (maximum 650mg) IV or PO and diphenhydramine 1 mg/kg (maximum 50mg) IV or PO.

  • DrugThymoglobulinStudies of ThymoglobulinThymoglobulin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Rabbit ATG will be administered at doses and days indicated above, infused through a 0.22 micrometer filter over 4-6 hours. Pre-medicate 30 minutes prior to ATG infusion with methylprednisolone 1 mg/kg IV, (max dose = 125 mg), acetaminophen 15 mg/kg dose (max dose = 650 mg) enterally and diphenhydramine 1 mg/kg/dose (max dose = 50 mg) enterally or IV.

    Also known as: Thymoglobulin

  • Cyclophosphamide 14.5 mg/kg is be given as a 2-hour infusion on day -6. If the patient is obese (actual body weight (ABW) \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (14.5 mg/kg/day) in IV continuous infusion will be provided per institutional guidelines. Hyperhydration is not required for 14.5 mg/kg cyclophosphamide doses. Cyclophosphamide will be administered at 50 mg/kg using ABW over 2 hours on days +3 and +4. If the patient is obese (ABW \>/= 125% of the ideal body weight (IBW)), cyclophosphamide should be dosed using the adjusted body weight (AdjBW): 0.5(ABW-IBW) + IBW. Uroprotection with MESNA (50 mg/kg/day) in IV continuous infusion as well as hyperhydration will be provided per institutional guidelines.

  • For all patients, fludarabine dosing will be model-based using Bayesian methodology IV every 24 hours on days -6 to -3 with a cumulative area under the curve (cAUC) of 20 mg\*hr/L.

  • RadiationTotal Body Irradiation

    For patients age \>/= 25 years, with myelodysplasia, or clonal hematopoiesis, total body irradiation will be 4 Gy, provided in two fractions on day -1. For all other patients, total body irradiation will be 2 Gy provided in a single fraction on day -1. Each dose of 2 Gy will be given at a dose rate between 1 and 1.9 Gy/minute prescribed to the midplane of the patient at the level of the umbilicus.

    Also known as: TBI

  • BiologicalCell TypesStudies of Cell TypesCell Types pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    On day 0 the cells will be infused per cell source specific institutional guidelines.

  • DrugFilgrastimStudies of FilgrastimFilgrastim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Beginning on day +5, patients will receive G-CSF SQ or IV 5 micrograms/kg once daily until post-nadir ANC \> 1500/μL for 3 consecutive days or \>3000/μL for 1 day.

    Also known as: Filgrastim

  • Tacrolimus will begin on day +5 at an initial dose of 0.03 mg/kg/day IV via continuous infusion. Goal trough levels will be 10-15 ug/mL until day +14 posttransplant, then decreased to a goal of 5-10 ng/mL thereafter. In the absence of GvHD, tacrolimus will discontinue at day +180 without a taper.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.

    Also known as: MMF

06

What researchers measure

Primary outcomes

  1. Incidence of grade 3-4 acute GvHD

    Incidence of grade 3-4 acute graft-versus host disease (GvHD) at 1 year post HCT.

    Time frame: 1 year post HCT

  2. Incidence of chronic GvHD-free, failure-free survival (GFFS)

    Incidence of chronic GvHD-free, failure-free survival (GFFS) 1 year post HCT

    Time frame: 1 year post HCT

  3. Incidence of chronic GvHD-free survival

    Incidence of chronic GvHD-free survival at 1 year post HCT

    Time frame: 1 year post HCT

Secondary outcomes

  1. Incidence of failure-free survival (GFFS)

    Incidence of chronic GvHD-free, failure-free survival (GFFS) 2 years post HC

    Time frame: 2 years post HCT

  2. Incidence of neutrophil recovery

    Incidence of neutrophil recovery at day 42 post HCT

    Time frame: Day 42 post HCT

  3. Incidence of platelet recovery

    Incidence of platelet recovery at 6 months post HCT

    Time frame: 6 months post HCT

  4. Incidence of grade 3-4 acute GvHD

    Incidence of grade 3-4 acute GvHD at 100 days post HCT

    Time frame: 100 days post HCT

  5. Incidence of any chronic GvHD

    Incidence of any chronic GvHD at 1 year post HCT

    Time frame: 1 year post HCT

  6. Overall survival

    Overall survival at 1 and 2 years

    Time frame: 1 and 2 years post HCT

  7. Incidence of chronic GvHD-free survival

    Incidence of chronic GvHD-free survival at 2 years post HCT

    Time frame: 2 years post HCT

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for May 2035, 130 months after the start.

Of 51 non-industry phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 111. This study's planned 130 months is above that.

Counting every sponsor, half of 59 studies reached it within 76 months; a quarter within 39 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
Jun 5, 2024
Primary completionEst.
May 1, 2035
CompletionEst.
May 1, 2036
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06412497
Responsible party
Sponsor
First posted
May 14, 2024
Start date
Jun 5, 2024
Primary completion
May 1, 2035 (estimated)
Completion
May 1, 2036 (estimated)
Last update
Jun 3, 2026

Study contacts

Meera Srikanthan, MD
Contact
srika038@umn.edu
(612) 626-2961

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Cell Types

Start the discussion